We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Lilly

News List

FDA extends review period for Eli Lilly’s rheumatoid arthritis drug europeanpharmaceuticalreview
January 17, 2017
The US Food and Drug Administration (FDA) has extended the review period for Eli Lilly and Incyte’s new drug application for investigational baricitinib, a once-daily oral medication for the treatment of moderate to severe rheumatoid arthritis (RA).
U.S. Court of Appeals Rules In Lilly's Favor On Alimta Vitamin Regimen Patent cphi-online
January 13, 2017
Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit has upheld the district court's decision and ruled in the company's favor regarding validity and infringement of the vitamin regimen patent for Alimta
Lilly to Adjust Organization and Leadership Structure to Better Align with Growth Opportunities lilly
January 06, 2017
Christi Shaw hired to lead Bio-Medicines; Conterno to assume additional geographic responsibilities, including Lilly USA leadership; Zulueta to lead International business

Previous page 1 2 3 4 5 6 7 8 9 10 ... 25 26 Next page